Expertise in
1
conditions

Dr. Ronald Mayfield

Endocrinology
Carolina Center For Diab & Endo
853 N Church St Ste 720C, 
Spartanburg, SC 
Referral required
Before you request
Expertise in
1
conditions
Carolina Center For Diab & Endo
853 N Church St Ste 720C, 
Spartanburg, SC 

Overview

Ronald Mayfield is an Endocrinologist practicing medicine in Spartanburg, South Carolina.

Dr. Mayfield is highly rated in 1 condition, according to our data. His clinical expertise encompasses Maturity Onset Diabetes of the Young, Type 2 Diabetes (T2D), and Obesity.

He is actively involved in clinical research, participating in 12 clinical trials.

Specialties

Endocrinology

Licenses

Internal Medicine in SC

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Carolina Center for Diab & Endo
853 N Church St Ste 720C, Spartanburg, SC 29303

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Mixed Dyslipidemia
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Mixed Dyslipidemia
Enrollment Status: Completed
Publish Date: April 14, 2026
Intervention Type: Drug
Study Phase: Phase 2
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia
A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia
Enrollment Status: Completed
Publish Date: March 24, 2026
Intervention Type: Drug
Study Drug: ARO-APOC3
Study Phase: Phase 2
A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes
A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes
Enrollment Status: Active_not_recruiting
Publish Date: December 12, 2025
Intervention Type: Drug
Study Phase: Phase 4
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: August 24, 2025
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes
A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Drug
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)
Enrollment Status: Completed
Publish Date: May 22, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Enrollment Status: Completed
Publish Date: May 16, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Enrollment Status: Completed
Publish Date: April 08, 2024
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)
A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)
Enrollment Status: Completed
Publish Date: November 02, 2023
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Lispro, Insulin Glargine
Study Phase: Phase 3
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Enrollment Status: Completed
Publish Date: February 14, 2022
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Glargine
Study Phase: Phase 3
View 9 Less Clinical Trials
Similar Doctors
Expertise in
63
conditions
Dr. Mayte Sandrin
Endocrinology
Expertise in
63
conditions
Dr. Mayte Sandrin
Endocrinology
Referral required

Medical Group Of The Carolinas-Diabetes & Endocrinology-Spartanburg

853 N Church St Ste 720C, 
Spartanburg, SC 
 (2.3 miles away)
864-560-6419
Languages Spoken:
English
See accepted insurances

Mayte Sandrin is an Endocrinologist practicing medicine in Spartanburg, South Carolina. Dr. Sandrin is highly rated in 63 conditions, according to our data. Her clinical expertise encompasses Type 2 Diabetes (T2D), Thyroid Storm, Type 1 Diabetes (T1D), and Hyperthyroidism.

Expertise in
33
conditions
Dr. John Schenck
Endocrinology
Expertise in
33
conditions
Dr. John Schenck
Endocrinology
Referral required

SMC - Diabetes & Endocrinology - Spartanburg

853 N Church St Ste 720C, 
Spartanburg, SC 
 (2.3 miles away)
864-560-6419
Languages Spoken:
English
See accepted insurances
Offers Telehealth

John Schenck is an Endocrinologist practicing medicine in Spartanburg, South Carolina. Dr. Schenck is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Hypothyroidism, Thyroid Storm, Hyperthyroidism, and Obesity in Children.

Expertise in
17
conditions
Dr. Cory R. White
Endocrinology
Expertise in
17
conditions
Dr. Cory R. White
Endocrinology
Referral required

Bon Secours Endocrinology

2 Innovation Drive, Suite 140, 
Greenville, SC 
 (24.2 miles away)
864-400-3680
Experience:
23+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

As a native of Greer, I am fortunate to serve patients in the Upstate. I completed medical school at UofSC, residency training at GHS, and fellowship training at MUSC. I am a Board Certified Endocrinologist and have been practicing at Bon Secours Endocrinology since 2016. Our practice sees a wide variety of adult endocrinology conditions, and my primary clinical interests include thyroid disorders, thyroid nodules, and thyroid cancer. Dr. White is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Anaplastic Thyroid Cancer, Follicular Thyroid Cancer, Thyroid Cancer, and Medullary Thyroid Carcinoma. Dr. White is board certified in American Board Of Internal Medicine and (Internal Medicine, Endocrinology, Diabetes & Metabolism).

Frequently Asked Questions about Dr. Ronald Mayfield

How do I make an appointment with Dr. Ronald Mayfield?

You can book an appointment with Dr. Ronald Mayfield by calling their office at 864-560-6279. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ronald Mayfield a top-rated expert for Maturity Onset Diabetes of the Young?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ronald Mayfield is classified as an Advanced expert for Maturity Onset Diabetes of the Young, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ronald Mayfield specialize in?

While Dr. Ronald Mayfield is a Endocrinology, they have specific expertise in Maturity Onset Diabetes of the Young, Type 2 Diabetes (T2D), and Obesity. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Endocrinology.

Does Dr. Ronald Mayfield accept my insurance?

Dr. Ronald Mayfield accepts most major insurance plans, including Aetna and Humana. We recommend calling the office directly at 864-560-6279 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mayfield's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile